Glenmark Africa

Key therapeutic categories

  • Dermatology
  • Gynaecology
  • Respiratory
  • Gastroenterology

Glenmark established its presence in Africa and the Middle East during the 1990s. We have operations in over 15 markets in the region with the key markets being South Africa, Kenya, Nigeria and Sudan.

The South African subsidiary is the largest subsidiary for Glenmark in the Africa region. Glenmark also has representative offices in Kenya and Egypt.

In December 2005, Glenmark acquired Bouwer Bartlett Pty. Ltd., a South African Sales and Marketing company, through its wholly owned Swiss subsidiary, Glenmark Pharmaceuticals SA.  Bouwer Bartlett’s pharmaceutical business unit produced, marketed, sold and distributed a range of dermatological products including brands like Synalar and Naseptin. They operated in the prescription market, pharmacy/health shops, and hospital & state sectors in South Africa. In addition to this, they also distributed products to other Southern African countries, namely Botswana, Zimbabwe and Namibia.

In the year 2006, , we enhanced our existing portfolio by acquiring a range of products from PD Pharmaceuticals as well as in–licensing a range of dermatological products from MZ Pharmaceuticals. These additions helped us immensely and contributed towards our strong presence in the dermatology segment of the region.

Markets The geographies we cater to:

  • Kenya
  • Nigeria
  • Sudan
  • South Africa
  • Tanzania
  • Uganda
  • Ethiopia
  • Egypt
  • Mauritius
  • Zimbabwe and Botswana
  • West Africa
  • Ghana
  • Zambia
  • Malawi